{"title":"文献综述","authors":"Guillermo A. Guerrero","doi":"10.33589/33.3.103","DOIUrl":null,"url":null,"abstract":"References 1. Mazzarella GF, et al. Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a 16-month therapy course. J Dermatolog Treat. 1997;8(3):189-192. 2. Piraccini BM, et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. J Eur Acad Dermatology Venereol. 2021;164(18):2017-2023. 3. Tanglertsampan C. Efficacy and safety of 3% minoxidil versus combined 3% minoxidil/0.1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study. J Med Assoc Thai. 2012;95(10):1312-1316. 4. Chandrashekar B, et al. Topical minoxidil fortified with finasteride: an account of maintenance of hair density after replacing oral finasteride. Indian Dermatol Online J. 2015;6(1):17. 5. Noor NM, et al. In vitro performance of dutasteride-nanostructured lipid carriers coated with lauric acid-chitosan oligomer for dermal delivery. Pharmaceutics. 2020 Oct 20;12(10):994. 6. Aval MMB, et al. Dutasteride nanoemulsion preparation to inhibit 5-alpha-hair follicle reductase enzymes in the hair follicle; an ex vivo study. IET Nanobiotechnol. 2023 Feb;17(1):13-21. n","PeriodicalId":14362,"journal":{"name":"International Society of Hair Restoration Surgery","volume":"67 1","pages":"103 - 103"},"PeriodicalIF":0.0000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Literature Review\",\"authors\":\"Guillermo A. Guerrero\",\"doi\":\"10.33589/33.3.103\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"References 1. Mazzarella GF, et al. Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a 16-month therapy course. J Dermatolog Treat. 1997;8(3):189-192. 2. Piraccini BM, et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. J Eur Acad Dermatology Venereol. 2021;164(18):2017-2023. 3. Tanglertsampan C. Efficacy and safety of 3% minoxidil versus combined 3% minoxidil/0.1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study. J Med Assoc Thai. 2012;95(10):1312-1316. 4. Chandrashekar B, et al. Topical minoxidil fortified with finasteride: an account of maintenance of hair density after replacing oral finasteride. Indian Dermatol Online J. 2015;6(1):17. 5. Noor NM, et al. In vitro performance of dutasteride-nanostructured lipid carriers coated with lauric acid-chitosan oligomer for dermal delivery. Pharmaceutics. 2020 Oct 20;12(10):994. 6. Aval MMB, et al. Dutasteride nanoemulsion preparation to inhibit 5-alpha-hair follicle reductase enzymes in the hair follicle; an ex vivo study. IET Nanobiotechnol. 2023 Feb;17(1):13-21. n\",\"PeriodicalId\":14362,\"journal\":{\"name\":\"International Society of Hair Restoration Surgery\",\"volume\":\"67 1\",\"pages\":\"103 - 103\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Society of Hair Restoration Surgery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33589/33.3.103\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Society of Hair Restoration Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33589/33.3.103","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
引用1。Mazzarella GF等。外用非那雄胺治疗雄激素性脱发。16个月疗程后的初步评估。中华皮肤科杂志。1997;8(3):189-192。2. Piraccini BM, et al。局部非那雄胺喷雾溶液治疗男性雄激素性脱发的疗效和安全性:一项III期随机对照临床试验中华皮肤科杂志，2013;32(6):391 - 391。3.3%米诺地尔与3%米诺地尔/0.1%非那雄胺联合治疗男性型脱发的疗效和安全性:一项随机、双盲、比较研究。中华医学杂志，2012;35(3):349 - 349。4. Chandrashekar B, et al。局部米诺地尔加非那雄胺:替代口服非那雄胺后维持毛发密度的研究。中国皮肤科杂志，2015;6(1):17。5. Noor NM，等。月桂酸-壳聚糖低聚物包被度他雄胺纳米脂质载体真皮递送的体外性能。制药学。2020年10月20日,12(10):994。6. 保兑百万桶,et al。抑制毛囊内5- α -毛囊还原酶的杜他雄胺纳米乳制备一项体外研究。生物质化学工程学报，2009;17(1):13-21。n
References 1. Mazzarella GF, et al. Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a 16-month therapy course. J Dermatolog Treat. 1997;8(3):189-192. 2. Piraccini BM, et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. J Eur Acad Dermatology Venereol. 2021;164(18):2017-2023. 3. Tanglertsampan C. Efficacy and safety of 3% minoxidil versus combined 3% minoxidil/0.1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study. J Med Assoc Thai. 2012;95(10):1312-1316. 4. Chandrashekar B, et al. Topical minoxidil fortified with finasteride: an account of maintenance of hair density after replacing oral finasteride. Indian Dermatol Online J. 2015;6(1):17. 5. Noor NM, et al. In vitro performance of dutasteride-nanostructured lipid carriers coated with lauric acid-chitosan oligomer for dermal delivery. Pharmaceutics. 2020 Oct 20;12(10):994. 6. Aval MMB, et al. Dutasteride nanoemulsion preparation to inhibit 5-alpha-hair follicle reductase enzymes in the hair follicle; an ex vivo study. IET Nanobiotechnol. 2023 Feb;17(1):13-21. n
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
